September 08, 2025 a 01:00 pm
UNH: Fundamental Ratio Analysis - UnitedHealth Group Incorporated
UnitedHealth Group Incorporated, a leader in the healthcare industry, shows promising growth potential driven by its diversified service offerings across several key segments. The company's robust financial health and strategic expansion in the healthcare sector make its stock an attractive prospect for investors. However, potential regulatory challenges and market competition remain critical considerations.
Fundamental Rating
UnitedHealth's fundamentals indicate a strong overall position with a rating of A- suggesting stable financial health and growth potential. Here’s a breakdown of the fundamental scores:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
Comparing historical to current scores aids in assessing the company's progression in maintaining its financial health.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-09-05 | 4 | 5 | 5 | 5 | 1 | 2 | 2 |
| Previous | 0 | 5 | 5 | 5 | 1 | 2 | 2 |
Analyst Price Targets
Analyst estimates point to potential growth, with a consensus target supporting continued investment. Here's a breakdown of target prices:
| High | Low | Median | Consensus |
|---|---|---|---|
| 575 | 198 | 357.5 | 358.75 |
Analyst Sentiment
The analyst sentiment remains positive, suggesting an overall buy indication for UnitedHealth's stock driven by its financial stability and market position.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 40 | |
| Hold | 6 | |
| Sell | 4 | |
| Strong Sell | 0 |
Conclusion
UnitedHealth Group's performance suggests a well-structured company with robust financial metrics, supporting investor confidence in its growth trajectory. The company's expansive service segments provide a competitive edge, though market fluctuations and regulatory landscape changes pose inherent risks. Overall, the buy consensus supports a positive outlook, with the fundamental analysis underscoring stability and potential for long-term gains.